Verlizia Biopharma-B (09887.HK): Verlixin (PD-L1/4-1BB bispecific antibody Opaticsumab monoclonal antibody, LBL-024) has been included in the priority review and approval process for the treatment of advanced non-small cell lung cancer.

Wisdom Financial News APP News, Betta Pharmaceuticals-B (09887.HK) announced that the biopharmaceutical Opdalisumab (PD-L1/4-1BB bispecific antibody, LBL024) for the treatment of advanced pulmonary extrapulmonary neuroendocrine tumors has been approved for priority review and approval by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE). This BLA application is based on positive results from a key registration clinical study led by Professor Shen Lin of Beijing Cancer Hospital, aimed at evaluating the effectiveness and safety of Opalisumab in patients with advanced EP-NEC who have progressed after receiving second-line or higher systemic treatment.